Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ESRRG | P62508 | 6/20 | 0.41 |
| ▸ | ESR1 | P03372 | 4/20 | 0.41 |
| ▸ | ESRRB | O95718 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12535509 | 0.94 | CYP1A2 (0.58) | CYP1A2ALDH1A1S1PR1S1PR3S1PR5 | |
| SCHEMBL28185799 | 0.93 | CYP1A2 (0.44) | CYP1A2ALDH1A1ESRRGESR1ESRRB | |
| SCHEMBL13014945 | 0.88 | CYP1A2 (0.56) | CYP1A2ALDH1A1S1PR1S1PR3S1PR5 | |
| SCHEMBL4065310 | 0.87 | — | — | |
| SCHEMBL236633 | 0.87 | — | — | |
| SCHEMBL21591048 | 0.87 | — | — | |
| SCHEMBL19376421 | 0.87 | CYP1A2 (0.57) | CYP1A2ALDH1A1S1PR1S1PR3S1PR5 | |
| Trifluoroacetic Acid SCHEMBL28185812 | 0.85 | CHRNB2 (0.41) | CYP1A2ESRRGESR1 | |
| SCHEMBL26729156 | 0.85 | CYP1A2 (0.44) | CYP1A2ALDH1A1ESRRGESR1ESRRB | |
| Trifluoromethanesulfonic Acid SCHEMBL28186554 | 0.84 | CYP1A2 (0.41) | CYP1A2ALDH1A1ESRRGESR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107427758-A | Utilize the separation of ion liquid solvent | 切弗朗菲利浦化学公司 | 2017-12-01 | — | — | CN | claimed |
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | claimed |
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | claimed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | claimed |
| US-7001904-B1 | Guanidine derivatives quinazoline and quinoline for use in the treatment of autoimmune diseases | ASTRAZENECA AB (SE) | 2006-02-21 | — | — | US | claimed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | claimed |
| US-6821965-B1 | IMPORTANT IN DISEASE OR MEDICAL CONDITIONS SUCH AS INFLAMMATION AND IMMUNOREGULATION | ASTERZENECA AB (SE) | 2004-11-23 | — | — | US | claimed |
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | claimed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| EP-1296973-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | AstraZeneca AB (SE) | 2003-04-02 | — | — | EP | claimed |
| EP-1102743-B1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2002-07-24 | — | — | EP | claimed |
| EP-1218353-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca UK Limited (GB) | 2002-07-03 | — | — | EP | claimed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | claimed |
| WO-2002000644-A1 | GUANIDINE DERIVATIVES OF QUINAZOLINE AND QUINOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2002-01-03 | — | — | WO | claimed |
| EP-1102743-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2001-05-30 | — | — | EP | claimed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | claimed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | claimed |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| WO-2001004102-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| WO-2000007980-A1 | AMIDE DERIVATIVES WHICH ARE USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | CYP1A2 4537/4885ALDH1A1 2260/4885ESRRG 196/4885 |
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | CYP1A2 482/4885ALDH1A1 257/4885ESRRG 4323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.